{
    "clinical_study": {
        "@rank": "132772", 
        "arm_group": {
            "arm_group_label": "Baricitinib + Digoxin", 
            "arm_group_type": "Experimental", 
            "description": "Digoxin - 0.5 mg administered orally, twice daily (BID), 12 hours apart on Day 1.  Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.\nBaricitinib - 10 mg administered orally, QD, on Days 8 through 16."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of baricitinib on the levels of digoxin\n      in the blood stream and how long it takes the body to remove digoxin.  This study will also\n      look at how safe and well-tolerated baricitinib is when given at the same time as digoxin in\n      healthy participants.  This study will last approximately 3-4 weeks."
        }, 
        "brief_title": "A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women not of child-bearing potential\n\n          -  Menopausal women\n\n          -  Have a body mass index of 18.0 to 29.0 kilograms per square meter (kg/m^2)\n\n        Exclusion Criteria:\n\n          -  Women who are lactating\n\n          -  Have previously completed or withdrawn from this study or any other study\n             investigating baricitinib\n\n          -  Currently enrolled in, have completed or discontinued within the last 90 days from a\n             clinical trial involving an investigational product\n\n          -  Have a pulse rate less than 50 beats per minute (bpm) at screening\n\n          -  Have a current or recent history (less than 30 days prior to screening and/or less\n             than 45 days prior to Day -1) of a clinically significant bacterial, fungal,\n             parasitic, viral (not including rhinopharyngitis), or mycobacterial infection\n\n          -  Have an absolute neutrophil count less than 2000 cells/microliter (2 \u00d7 10^9/liter) at\n             screening or Day -1\n\n          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human\n             HIV antibodies\n\n          -  Have been exposed to a live vaccine within 12 weeks prior to the first dose or\n             expected to need/receive a live vaccine\n\n          -  Intend to use over-the-counter or prescription medication and/or herbal supplements\n             within 14 days prior to dosing and during the study\n\n          -  Have used or intend to use any drugs or substances that are known to be substrates,\n             inducers, or inhibitors of P-glycoprotein (P-gp) within 30 days prior to dosing and\n             throughout the study\n\n          -  Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior\n             to the first dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859078", 
            "org_study_id": "14609", 
            "secondary_id": "I4V-MC-JAGL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Baricitinib + Digoxin", 
                "description": "Administered orally", 
                "intervention_name": "Baricitinib", 
                "intervention_type": "Drug", 
                "other_name": "LY3009104"
            }, 
            {
                "arm_group_label": "Baricitinib + Digoxin", 
                "description": "Administered orally", 
                "intervention_name": "Digoxin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "state": "West Yorkshire", 
                    "zip": "LS2 9LH"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Baricitinib on the Pharmacokinetics of Digoxin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours post Day 16 dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours post Day 16 dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve During 1 Dosing Interval of Digoxin (AUC\u03c4)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours post Day 16 dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859078"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Amount of Drug Excreted Unchanged Over Each Urine Collection Interval (Ae) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours post Day 16 dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Renal Clearance (CLr) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours post Day 16 dose"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}